Alison R. Moliterno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alison R. Moliterno has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
Jaroslaw P. Maciejewski
14 shared publicationsKeith W. Pratz
13 shared publicationsMichael A. McDevitt
13 shared publications- Robert L. Dilley
Department of Cancer Biology, Penn Center for Genome Integrity, Basser Center for BRCA, Perelman School of Medicine, University of Pennsylvania
13 shared publications - Weijie Poh
Graduate Program in Pathobiology, Johns Hopkins School of Medicine, Baltimore, Maryland
13 shared publications James G. Herman
12 shared publications
Latest Publications
- Open Access
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table 6: Transcripts underexpressed in IMF samples with JAK2V617F mutation
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table 6: Transcripts underexpressed in IMF samples with JAK2V617F mutation
- Open Access
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table 3: Loci that are differentially hypomethylated in IMF with JAK2V617F mutations when compared to controls
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table 3: Loci that are differentially hypomethylated in IMF with JAK2V617F mutations when compared to controls
- Open Access
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supplementary Figures S1-S7 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supplementary Figures S1-S7 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
- Open Access
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table 5: Transcripts overrexpressed in IMF samples with JAK2V617F mutation
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table 5: Transcripts overrexpressed in IMF samples with JAK2V617F mutation
- Open Access
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table 4: Loci that are differentially methylated in IMF with JAK2V617F mutations when compared to controls
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table 4: Loci that are differentially methylated in IMF with JAK2V617F mutations when compared to controls
- Open Access
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table 1: Transcripts associated with loss of cytosine methylation and increased gene expression in FDCP cells with JAK2V617F compared to FDCP with WT Jak2
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table 1: Transcripts associated with loss of cytosine methylation and increased gene expression in FDCP cells with JAK2V617F compared to FDCP with WT Jak2
- Open Access
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table 2: Patient Characteristics of IMF patients
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table 2: Patient Characteristics of IMF patients
- Open Access
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table S7 : Functional pathways differentially expressed and hydroxymethylated in Jak2V617F murine samples
- 12 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis
Supp Table S7 : Functional pathways differentially expressed and hydroxymethylated in Jak2V617F murine samples
- 22 May 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (4) , 325-335
Silent cerebral infarction during immune TTP remission - prevalence, predictors, and impact on cognition
Immune TTP (iTTP) survivors have increased risk of cardiovascular disease including stroke, and report persistent cognitive difficulties during remission. We conducted this prospective study of iTTP survivors in clinical remission to determine the prevalence of silent cerebral infarction (SCI), defined as magnetic resonance imaging (MRI) evidence of brain infarction without corresponding overt neuro-deficits, during clinical remission. We also tested the hypothesis that SCI is associated with cognitive impairment assessed using the NIH ToolBox cognition battery. We used fully corrected T scores adjusted for age, sex, race, and education. Based on DSM-5 criteria, we defined mild and major cognitive impairment as T-scores that are 1-2 SD and > 2 SD below the mean on at least one test, respectively. Forty-two patients have been enrolled, with 36 completing MRI.SCI was present in 50% (18) , of which 8 (44.4%) had prior overt stroke including during acute iTTP. Patients with SCI had higher rates of cognitive impairment (66.7% vs. 27.7%, P=0.026) including major cognitive impairment (50% vs. 5.6%, P=0.010). In separate logistic regression models, SCI was associated with any (mild or major) cognitive impairment [OR 10.5 (95% CI 1.45 - 76.63); P = 0.020] and major cognitive impairment [OR 7.98 (95% CI 1.11 - 57.27); P = 0.039] after adjusting for history of stroke and Beck depression inventory scores. In summary, MRI evidence of brain infarction is common in iTTP survivors; the strong association of SCI with impaired cognition suggests that these 'silent' infarcts are neither silent nor innocuous.
- 22 May 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (4) , 325-335
Silent cerebral infarction during immune TTP remission - prevalence, predictors, and impact on cognition
Immune TTP (iTTP) survivors have increased risk of cardiovascular disease including stroke, and report persistent cognitive difficulties during remission. We conducted this prospective study of iTTP survivors in clinical remission to determine the prevalence of silent cerebral infarction (SCI), defined as magnetic resonance imaging (MRI) evidence of brain infarction without corresponding overt neuro-deficits, during clinical remission. We also tested the hypothesis that SCI is associated with cognitive impairment assessed using the NIH ToolBox cognition battery. We used fully corrected T scores adjusted for age, sex, race, and education. Based on DSM-5 criteria, we defined mild and major cognitive impairment as T-scores that are 1-2 SD and > 2 SD below the mean on at least one test, respectively. Forty-two patients have been enrolled, with 36 completing MRI.SCI was present in 50% (18) , of which 8 (44.4%) had prior overt stroke including during acute iTTP. Patients with SCI had higher rates of cognitive impairment (66.7% vs. 27.7%, P=0.026) including major cognitive impairment (50% vs. 5.6%, P=0.010). In separate logistic regression models, SCI was associated with any (mild or major) cognitive impairment [OR 10.5 (95% CI 1.45 - 76.63); P = 0.020] and major cognitive impairment [OR 7.98 (95% CI 1.11 - 57.27); P = 0.039] after adjusting for history of stroke and Beck depression inventory scores. In summary, MRI evidence of brain infarction is common in iTTP survivors; the strong association of SCI with impaired cognition suggests that these 'silent' infarcts are neither silent nor innocuous.
- Top Cited PapersOpen Access
- 20 April 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (16) , 1934-1942
JAK2 V617F allele burden in polycythemia vera: burden of proof
Polycythemia vera (PV) is a hematopoietic stem cell neoplasm defined by activating somatic mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells, platelets, and neutrophils; a significant burden of disease-specific symptoms; high rates of vascular events; and evolution to a myelofibrosis phase or acute leukemia. The JAK2V617F variant allele frequency (VAF) is a key determinant of outcomes in PV, including thrombosis and myelofibrotic progression. Here, we critically review the dynamic role of JAK2V617F mutation burden in the pathogenesis and natural history of PV, the suitability of JAK2V617F VAF as a diagnostic and prognostic biomarker, and the utility of JAK2V617F VAF reduction in PV treatment.
- 20 April 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (16) , 1934-1942
Top Cited PapersOpen AccessJAK2 V617F allele burden in polycythemia vera: burden of proof
Polycythemia vera (PV) is a hematopoietic stem cell neoplasm defined by activating somatic mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells, platelets, and neutrophils; a significant burden of disease-specific symptoms; high rates of vascular events; and evolution to a myelofibrosis phase or acute leukemia. The JAK2V617F variant allele frequency (VAF) is a key determinant of outcomes in PV, including thrombosis and myelofibrotic progression. Here, we critically review the dynamic role of JAK2V617F mutation burden in the pathogenesis and natural history of PV, the suitability of JAK2V617F VAF as a diagnostic and prognostic biomarker, and the utility of JAK2V617F VAF reduction in PV treatment.